blinatumomab
Blinatumomab Increases Disease-Free Survival for Children With Leukemia
Children with B-acute lymphoblastic leukemia who received blinatumomab plus standard chemotherapy were 61% less ...
JANUARY 15, 2025
T-Cell Engager Called Major Breakthrough In Children With B-Cell ALL
The T-cell engager blinatumomab (Blincyto, Amgen) was characterized as a “major breakthrough” in ...
DECEMBER 20, 2024
Blincyto Approved as Consolidation for CD19-Positive Philadelphia Chromosome–Negative B-Cell Precursor ALL
The FDA has approved blinatumomab (Blincyto, Amgen) for adult and pediatric patients aged 1 month and older with ...
JUNE 17, 2024
Report from ASH 2019: Large Benefit With Blinatumomab in Trial of Younger B-ALL Patients
ORLANDO, FLA.—In children, adolescents and young adults with B-cell acute lymphoblastic leukemia who have ...
DECEMBER 23, 2019
FDA Approves Blincyto for ALL Pts with Minimal Residual Disease
Blincyto is the first and only FDA-approved therapy for patients who have ALL that is in remission but who still ...
MARCH 29, 2018
Blincyto Approved for Relapsed or Refractory B-cell ALL
The FDA granted full approval to blinatumumab for relapsed or refractory B-cell precursor acute lymphoblastic ...
JULY 12, 2017
Blincyto Granted Priority Review to Expand ALL Indication
The drug was granted priority review to expand the indication for the treatment of all patients with relapsed or ...
MARCH 30, 2017
Blincyto Approved for Pediatric Patients With B-Cell Precursor ALL
The therapy was approved to treat pediatric patients with Philadelphia chromosome–negative (Ph-) relapsed or ...
OCTOBER 13, 2016